Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

Delayed Quote. Delayed  - 02/09 05:32:59 am
57.06 GBp   +0.55%
02/04 VERNALIS : "Vernalis" or the "Company") Notice of Results for the Si..
01/09 VERNALIS : Announces Adenosine Antagonist Licensee
01/06 VERNALIS : Reveals US-Based Corvus Pharmaceuticals As Licensee
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Vernalis plc
Researches and develops pharmaceutical products

Vernalis Plc is a research and development stage pharmaceutical company.

The company provides pharmaceutical products for a range of medical disorders.

It focuses on de novo fragment and structure based drug discovery and pre clinical and clinical development.

The group has one marketed product, frovatriptan, for the acute treatment of migraines, as well as eight programmes in its NCE development pipeline.

The company was founded by Keith G. McCullagh in 1986 and is headquartered in Wokingham, the United Kingdom.

Number of employees : 91 persons.
Sales per Businesses
2015
GBP (in Million)%
Pharmaceuticals13.26100%
Sales per Regions
2015
GBP (in Million)%
Rest of Europe10.2577.4%
Rest of the World2.3217.5%
North America0.6695%
United Kingdom0.0160.1%
Managers
NameAgeSinceTitle
Ian Garland502008Chief Executive Officer & Executive Director
Peter John Fellner, PhD712003Non-Executive Chairman
David MacKney482009Chief Financial Officer & Executive Director
Mike Wood-2004Research Director
Pascal Borderies-2014Senior Vice President-Medical Affairs
Carol C. Ferguson692003Senior Independent Non-Executive Director
Nigel Sheail502011Independent Non-Executive Director
Ian David Gilham, PhD552015Non-Executive Director
Lisa Amster Schoenberg, MBA492015Non-Executive Director
Kevin Kissane602010Secretary & General Counsel
Shareholders
NameEquities%
Invesco Asset Management Ltd. 160,122,166 36.0%
Woodford Investment Management LLP 107,119,127 24.1%
GAM London Ltd. 43,233,403 9.71%
Legal & General Investment Management Ltd. 29,022,162 6.52%
Aviva Investors Global Services Ltd. 27,352,207 6.14%
Rothschild Bank AG 11,129,000 2.50%
Majedie Asset Management Ltd. 9,844,819 2.21%
OppenheimerFunds, Inc. 9,712,000 2.18%
EdenTree Investment Management Ltd. 4,750,000 1.07%
River & Mercantile Asset Management LLP 4,728,601 1.06%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - NEC
Advertisement
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
INCYTE CORPORATIO..
CELLTRION, INC.
LONZA GROUP AG
QUINTILES TRANSNA..
UNITED THERAPEUTI..
ALNYLAM PHARMACEU..
QIAGEN NV
ALKERMES PLC
SEATTLE GENETICS,..
INTREXON CORP
IONIS PHARMACEUTI..
ICON PLC
WUXI PHARMATECH (..
BIO-TECHNE CORP
CHARLES RIVER LAB..
PAREXEL INTERNATI..
ANACOR PHARMACEUT..
BB BIOTECH AG
-
PRA HEALTH SCIENC..
HANGZHOU TIGERMED..
Sector Biotechnology & Medical Research
Vernalis plc : Connections
Biosurfit SA
The Institute of Chartered Accountants of Scotland
Bayer HealthCare
Multiplicom NV
Concepta Diagnostics Ltd.
Chartered Accountants Compensation Scheme Ltd.
Stowheath Ltd.
Company contact information
Vernalis Plc
100 Berkshire Place
Wharfedale Road
Winnersh, Berkshire RG41 5RD

Phone : +44.118.938.0000
Fax : +44.118.938.0001
Web : www.vernalis.com
© 2016 People , Fundamentals and Ownership